Beijing Strong Biotechnologies Inc (300406) - Total Assets
Based on the latest financial reports, Beijing Strong Biotechnologies Inc (300406) holds total assets worth CN¥5.30 Billion CNY (≈ $774.83 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Beijing Strong Biotechnologies Inc (300406) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Beijing Strong Biotechnologies Inc - Total Assets Trend (2011–2024)
This chart illustrates how Beijing Strong Biotechnologies Inc's total assets have evolved over time, based on quarterly financial data. Explore Beijing Strong Biotechnologies Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Beijing Strong Biotechnologies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Strong Biotechnologies Inc's total assets of CN¥5.30 Billion consist of 46.3% current assets and 53.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.7% |
| Accounts Receivable | CN¥1.13 Billion | 20.2% |
| Inventory | CN¥220.68 Million | 4.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥57.08 Million | 1.0% |
| Goodwill | CN¥1.67 Billion | 30.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Beijing Strong Biotechnologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Strong Biotechnologies Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Strong Biotechnologies Inc's current assets represent 46.3% of total assets in 2024, a decrease from 78.0% in 2011.
- Cash Position: Cash and equivalents constituted 18.7% of total assets in 2024, down from 26.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 30.0% of total assets.
Beijing Strong Biotechnologies Inc Competitors by Total Assets
Key competitors of Beijing Strong Biotechnologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Beijing Strong Biotechnologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.66 | 9.03 | 7.30 |
| Quick Ratio | 10.63 | 8.21 | 6.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.22 Billion | CN¥2.31 Billion | CN¥1.53 Billion |
Beijing Strong Biotechnologies Inc - Advanced Valuation Insights
This section examines the relationship between Beijing Strong Biotechnologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | CN¥5.57 Billion |
| Market Capitalization | $972.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Strong Biotechnologies Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Strong Biotechnologies Inc's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Strong Biotechnologies Inc (2011–2024)
The table below shows the annual total assets of Beijing Strong Biotechnologies Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.57 Billion ≈ $815.79 Million |
+7.71% |
| 2023-12-31 | CN¥5.18 Billion ≈ $757.37 Million |
+12.20% |
| 2022-12-31 | CN¥4.61 Billion ≈ $675.01 Million |
+6.79% |
| 2021-12-31 | CN¥4.32 Billion ≈ $632.11 Million |
+8.98% |
| 2020-12-31 | CN¥3.96 Billion ≈ $580.01 Million |
+84.01% |
| 2019-12-31 | CN¥2.15 Billion ≈ $315.20 Million |
+15.51% |
| 2018-12-31 | CN¥1.86 Billion ≈ $272.87 Million |
+4.84% |
| 2017-12-31 | CN¥1.78 Billion ≈ $260.28 Million |
+20.91% |
| 2016-12-31 | CN¥1.47 Billion ≈ $215.27 Million |
+16.59% |
| 2015-12-31 | CN¥1.26 Billion ≈ $184.64 Million |
+20.80% |
| 2014-12-31 | CN¥1.04 Billion ≈ $152.84 Million |
+100.52% |
| 2013-12-31 | CN¥520.88 Million ≈ $76.22 Million |
+20.44% |
| 2012-12-31 | CN¥432.48 Million ≈ $63.29 Million |
+36.56% |
| 2011-12-31 | CN¥316.70 Million ≈ $46.34 Million |
-- |
About Beijing Strong Biotechnologies Inc
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. The company offers biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activ… Read more